The current case of quinolones: Synthetic approaches and antibacterial activity

Molecules

Volumn 21, Issue 4, 2016, Pages

  Naeem, Abdul ^a   Badshah, Syed Lal ^a   Muska, Mairman ^a   Ahmad, Nasir ^a   Khan, Khalid ^a  

^a UNIVERSITY OF PESHAWAR   (Pakistan)

Author keywords

Analogues; Gyrase; Quinolones; Resistance; Topoisomerase IV

Indexed keywords

ANTIINFECTIVE AGENT; CHLOROQUINE; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE IV; GYRASE INHIBITOR; QUINOLONE DERIVATIVE;

ANTAGONISTS AND INHIBITORS; ANTIBIOTIC RESISTANCE; BACTERIAL INFECTIONS; CHEMISTRY; DRUG EFFECTS; ESCHERICHIA COLI; GENETICS; HUMAN; MICROBIOLOGY; PATHOGENICITY;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CHLOROQUINE; DNA GYRASE; DNA TOPOISOMERASE IV; DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI; HUMANS; QUINOLONES; TOPOISOMERASE II INHIBITORS;

EID: 84968583497     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules21040268     Document Type: Review

References (125)

1. Armstrong, G.L.; Conn, L.A.; Pinner, R.W. Trends in infectious disease mortality in the united states during the 20th century. JAMA 1999, 281, 61-66.
2. Cross, R.M.; Flanigan, D.L.; Monastyrskyi, A.; LaCrue, A.N.; Saenz, F.E.; Maignan, J.R.; Mutka, T.S.; White, K.L.; Shackleford, D.M.; Bathurst, I. Orally bioavailable 6-chloro-7-methoxy-4(1H)-quinolones efficacious against multiple stages of plasmodium. J. Med. Chem. 2014, 57, 8860-8879.
3. Baharoglu, Z.; Garriss, G.; Mazel, D. Multiple pathways of genome plasticity leading to development of antibiotic resistance. Antibiotics 2013, 2, 288-315.
4. Walsh, C. Where will new antibiotics come from? Nat. Rev. Microbiol. 2003, 1, 65-70.
5. Livermore, D.M. Has the era of untreatable infections arrived? J. Antimicrob. Chemother. 2009, 64, i29-i36.
6. Hu, W.; Lin, J.-P.; Song, L.-R.; Long, Y.-Q. Direct synthesis of 2-aryl-4-quinolones via transition-metal-free intramolecular oxidative C (sp3)-H/C(sp3 )-H coupling. Org. Lett. 2015, 17, 1268-1271.
7. Oliphant, C.M.; Green, G.M. Quinolones: A comprehensive review. Am. Fam. Physician 2002, 65, 455-464.
8. Lesher, G.Y.; Froelich, E.J.; Gruett, M.D.; Bailey, J.H.; Brundage, R.P. 1,8-naphthyridine derivatives. A new class of chemotherapeutic agents. J. Med. Chem. 1962, 5, 1063-1065.
9. Wu, J.; Xiang, S.; Zeng, J.; Leow, M.; Liu, X.-W. Practical route to 2-quinolinones via a pd-catalyzed C-H bond activation/C-C bond formation/cyclization cascade reaction. Org. Lett. 2014, 17, 222-225.
10. Emmerson, A.M.; Jones, A.M. The quinolones: Decades of development and use. J. Antimicrob. Chemother. 2003, 51, 13-20.
11. Andriole, V.T. The quinolones: Past, present, and future. Clin. Infect. Dis. 2005, 41, S113-S119.
12. Bisacchi, G.S. Origins of the quinolone class of antibacterials: An expanded discovery story. J. Med. Chem. 2015, 58, 4874-4882.
13. Mitscher, L.A. Bacterial topoisomerase inhibitors: Quinolone and pyridone antibacterial agents. Chem. Rev. 2005, 105, 559-592.
14. Domagala, J.M. Structure-activity and structure-side-effect relationships for the quinolone antibacterials. J. Antimicrob. Chemother. 1994, 33, 685-706.
15. Guo, X.; Liu, M.L.; Guo, H.Y.; Wang, Y.C.; Wang, J.X. Synthesis and in vitro antibacterial activity of 7-(3-amino-6,7-dihydro-2-methyl-2H-pyrazolo[4,3-c]pyridin-5(4H)-yl) fluoroquinolone derivatives. Molecules 2011, 16, 2626-2635.
16. Aldred, K.J.; Kerns, R.J.; Osheroff, N. Mechanism of quinolone action and resistance. Biochemistry 2014, 53, 1565-1574.
17. Sharma, P.C.; Jain, A.; Jain, S. Fluoroquinolone antibacterials: A review on chemistry, microbiology and therapeutic prospects. Acta. Pol. Pharm. 2009, 66, 587-604.
18. Liu, M.L.; Guo, H.Y. Evolution of the quinolones. World Notes Antibiot. 2006, 27, 69-75.
19. Blasco, C.; PicoÌ, Y. Development of an improved method for trace analysis of quinolones in eggs of laying hens and wildlife species using molecularly imprinted polymers. J. Agric. Food Chem. 2012, 60, 11005-11014.
20. Cross, R.M.; Maignan, J.R.; Mutka, T.S.; Luong, L.; Sargent, J.; Kyle, D.E.; Manetsch, R. Optimization of 1,2,3,4-tetrahydroacridin-9(10H)-ones as antimalarials utilizing structure-activity and structure-property relationships. J. Med. Chem 2011, 54, 4399-4426.
21. Ferguson, J.; Zeng, F.; Alwis, N.; Alper, H. Synthesis of 2 (1H)-quinolinones via Pd-catalyzed oxidative cyclocarbonylation of 2-vinylanilines. Org. Lett. 2013, 15, 1998-2001.
22. Kang, D.; Hong, S. Rh (III) and Ru (II)-catalyzed site-selective C-H alkynylation of quinolones. Org. Lett. 2015, 17, 1938-1941.
23. Saito, K.; Moriya, Y.; Akiyama, T. Chiral phosphoric acid catalyzed asymmetric synthesis of 2-substituted 2, 3-dihydro-4-quinolones by a protecting-group-free approach. Org. Lett. 2015, 17, 3202-3205.
24. Kanagaraj, K.; Pitchumani, K. Per-6-amino-β-cyclodextrin as a chiral base catalyst promoting one-pot asymmetric synthesis of 2-aryl-2,3-dihydro-4-quinolones. J. Org. Chem. 2013, 78, 744-751.
25. Åkerbladh, L.; Nordeman, P.; Wejdemar, M.; Odell, L.R.; Larhed, M. Synthesis of 4-quinolones via a carbonylative Sonogashira cross-coupling using molybdenum hexacarbonyl as a CO source. J. Org. Chem. 2015, 80, 1464-1471.
26. Monastyrskyi, A.; Namelikonda, N.K.; Manetsch, R. Metal-free arylation of ethyl acetoacetate with hypervalent diaryliodonium salts: An immediate access to diverse 3-aryl-4 (1H)-quinolones. J. Org. Chem. 2015, 80, 2513-2520.
27. Wang, W.; Peng, X.; Qin, X.; Zhao, X.; Ma, C.; Tung, C.-H.; Xu, Z. Synthesis of quinolinones with palladium-catalyzed oxidative annulation between acrylamides and arynes. J. Org. Chem. 2015, 80, 2835-2841.
28. Manikandan, R.; Jeganmohan, M. Ruthenium-catalyzed cyclization of anilides with substituted propiolates or acrylates: An efficient route to 2-quinolinones. Org. Lett. 2014, 16, 3568-3571.
29. Leung, S.C.; Gibbons, P.; Amewu, R.; Nixon, G.L.; Pidathala, C.; Hong, W.D.; Pacorel, B.; Berry, N.G.; Sharma, R.; Stocks, P.A.; et al. Identification, design and biological evaluation of heterocyclic quinolones targeting Plasmodium falciparum type II NADH: Quinone oxidoreductase (PfNDH2). J. Med. Chem. 2012, 55, 1844-1857.
30. Patel, N.B.; Pathak, K.K. Pyridoquinolones containing azetidinones: Synthesis and their biological evaluation. Med. Chem. Res. 2011, 21, 2044-2055.
31. Patel, N.B.; Chauhan, H.I. Novel pyridoquinolones of sulfonamides, thioureas and amines and their antimicrobial activity. Indian J. Heterocycl. Chem. 2005, 15, 39-42.
32. Patel, N.B.; Modi, S.H. Synthesis and antimicrobial activity of novel 6-hydroxy-4-oxo-pyrido[2,3-H] quinoline-3[(substituted aryl ureido/piperazinyl)carbonyl]. Indian J. Pharm. Educational Res. 2010, 44, 8-21.
33. Patel, N.B.; Patel, J.C. Synthesis and antimicrobial study of fluoroquinolone based 4-thiozolidinones. Med. Chem. Res. 2010, 19, 757-770.
34. Patel, N.B.; Patel, J.C. Synthesis and antimicrobial activities of 2-azetidinyl-4-quinazolinone derivatives of diclofenac analogue. Med. Chem. Res. 2011, 20, 511-521.
35. Patel, N.B.; Patel, J.C.; Modi, S.H. Synthesis and antimicrobial activity of carbonyl pyridoquinolones containing urea and piperazine residue. J. Saudi Chem. Soc. 2010, 15, 167-176.
36. Patel, N.B.; Patel, S.D.; Chauhan, H.I. Synthesis and in vitro microbial activities of amides of pyridoquinolone. Med. Chem. Res. 2011, 20, 1054-1067.
37. Komarnicka, U.K.; Starosta, R.; Guz-Regner, K.; Bugla-Płoskoñska, G.; Kyzioł, A.; Jżowska-Bojczuk, M. Phosphine derivatives of sparfloxacin-Synthesis, structures and in vitro activity. J. Mol. Struct. 2015, 1096, 55-63.
38. Plech, T.; Wujec, M.; Kosikowska, U.; Malm, A.; Rajtar, B.; Polz-Dacewicz, M. Synthesis and in vitro activity of 1,2,4-triazole-ciprofloxacin hybrids against drug-susceptible and drug-resistant bacteria. Eur. J. Med. Chem. 2013, 60, 128-134.
39. Parkinson, E.I.; Bair, J.S.; Nakamura, B.A.; Lee, H.Y.; Kuttab, H.I.; Southgate, E.H.; Lezmi, S.; Lau, G.W.; Hergenrother, P.J. Deoxynybomycins inhibit mutant DNA gyrase and rescue mice infected with fluoroquinolone-resistant bacteria. Nat. Commun. 2015, 6.
40. Kern, G. Inhibition of Neisseria gonorrhoeae type II topoisomerases by the novel spiropyrimidinetrione azd0914. J. Biol. Chem. 2015, 290, 20984-20994.
41. Soni, K. Fluoroquinolones: Chemistry & action-A review. Indo Global J. Pharm. Sci. 2012, 2, 43-53.
42. Mohammadhosseini, N.; Alipanahi, Z.; Alipour, E.; Emami, S.; Faramarzi, M.; Samadi, N.; Khoshnevis, N.; Shafiee, A.; Foroumadi, A. Synthesis and antibacterial activity of novel levofloxacin derivatives containing a substituted thienylethyl moiety. DARU J. Pharm. Sci. 2012, 20.
43. Vijan, L.E.; Giosanu, D. Binding of norfloxacin, enoxacin and enrofloxacin to calf thymus DNA. Rev. Roum. Chim. 2012, 57, 823-827.
44. Mdluli, K.; Ma, Z. Mycobacterium tuberculosis DNA gyrase as a target for drug discovery. Infect. Disord. Drug Targets 2007, 7, 159-168.
45. Hawtin, R.E.; Stockett, D.E.; Byl, J.A.; McDowell, R.S.; Nguyen, T.; Arkin, M.R.; Conroy, A.; Yang, W.; Osheroff, N.; Fox, J.A. Voreloxin is an anticancer quinolone derivative that intercalates DNA and poisons topoisomerase II. PLoS ONE 2010, 5.
46. Cazedey, E.C.L.; Salgado, H.R. Development and validation of a microbiological agar assay for determination of orbifloxacin in pharmaceutical preparations. Pharmaceutics 2011, 3, 572-581.
47. Qin, W.; Panunzio, M.; Biondi, S. Beta-lactam antibiotics renaissance. Antibiotics 2014, 3, 193-215.
48. Zhao, S.; Li, X.; Ra, Y.; Li, C.; Jiang, H.; Li, J.; Qu, Z.; Zhang, S.; He, F.; Wan, Y. Developing and optimizing an immunoaffinity cleanup technique for determination of quinolones from chicken muscle. J. Agric. Food Chem. 2009, 57, 365-371.
49. Owens, R.C.; Ambrose, P.G. Clinical use of the fluoroquinolones. Med. Clin. N. Am. 2000, 84, 1447-1469.
50. Long, T.E.; Keding, L.C.; Lewis, D.D.; Anstead, M.I.; Ryan Withers, T.; Yu, H.D. Anionic fluoroquinolones as antibacterials against biofilm-producing Pseudomonas aeruginosa. Bioorg. Med. Chem. Lett. 2016, 26, 1305-1309.
51. Bradley, J.; Jackson, M. The use of systemic and topical fluoroquinolones. Pediatrics 2011, 128, e1034-e1045.
52. Takiff, H.; Guerrero, E. Current prospects for the fluoroquinolones as first-line tuberculosis therapy. Antimicrob. Agents Chemother. 2011, 55, 5421-5429.
53. Sun, Z.; Zhang, J.; Zhang, X.; Wang, S.; Zhang, Y.; Li, C. Comparison of gyrA gene mutations between laboratory-selected ofloxacin-resistant Mycobacterium tuberculosis strains and clinical isolates. Int. J. Antimicrob. Agents 2008, 31, 115-121.
54. Avalos, E.; Catanzaro, D.; Catanzaro, A.; Ganiats, T.; Brodine, S.; Alcaraz, J.; Rodwell, T. Frequency and geographic distribution of gyrA and gyrB mutations associated with fluoroquinolone resistance in clinical Mycobacterium tuberculosis isolates: A systematic review. PLoS ONE 2015, 10, e0120470.
55. Nosova, E.Y.; Bukatina, A.A.; Isaeva, Y.D.; Makarova, M.V.; Galkina, K.Y.; Moroz, A.M. Analysis of mutations in the gyrA and gyrB genes and their association with the resistance of Mycobacterium tuberculosis to levofloxacin, moxifloxacin and gatifloxacin. J. Med. Microbiol. 2013, 62, 108-113.
56. Lu, J.; Liu, M.; Wang, Y.; Pang, Y.; Zhao, Z. Mechanisms of fluoroquinolone monoresistance in mycobacterium tuberculosis. FEMS Microbiol. Lett. 2014, 353, 40-48.
57. Zhang, Z.; Lu, J.; Wang, Y.; Pang, Y.; Zhao, Y. Prevalence and molecular characterization of fluoroquinolone-resistant Mycobacterium tuberculosis isolates in china. Antimicrob. Agents Chemother. 2014, 58, 364-369.
58. Zhang, Y. Advances in the treatment of tuberculosis. Clin. Pharmacol. Ther. 2007, 82, 595-600.
59. Zhu, C.; Zhang, Y.; Shen, Y.; Siu, G.K.H.; Wu, W.; Qian, X.; Deng, G.; Xu, Y.; Lau, R.; Fan, X.; et al. Molecular characterization of fluoroquinolone-resistant Mycobacterium tuberculosis clinical isolates from Shanghai, China. Diagn. Microbiol. Infect. Dis. 2012, 73, 260-263.
60. Shi, R.; Zhang, J.; Li, C.; Kazumi, Y.; Sugawara, I. Emergence of ofloxacin resistance in Mycobacterium tuberculosis clinical isolates from china as determined by gyrA mutation analysis using denaturing high-pressure liquid chromatography and DNA sequencing. J. Clin. Microbiol. 2006, 44, 4566-4568.
61. Umubyeyi, A.N. Limited fluoroquinolone resistance among Mycobacterium tuberculosis isolates from rwanda: Results of a national survey. J. Antimicrob. Chemother. 2007, 59, 1031-1033.
62. Hu, Q.; Yin, L.; Ali, A.; Cooke, A.J.; Bennett, J.; Ratcliffe, P.; Lo, M.M.-C.; Metzger, E.; Hoyt, S.; Hartmann, R.W. Novel pyridyl substituted 4,5-dihydro-[1,2,4]triazolo[4,3-a]quinolines as potent and selective aldosterone synthase inhibitors with improved in vitro metabolic stability. J. Med. Chem. 2015, 58, 2530-2537.
63. Pescatori, L.; Métifiot, M.; Chung, S.; Masoaka, T.; Cuzzucoli Crucitti, G.; Messore, A.; Pupo, G.; Madia, V.N.; Saccoliti, F.; Scipione, L.; et al. N-substituted quinolinonyl diketo acid derivatives as HIV integrase strand transfer inhibitors and their activity against RNase H function of reverse transcriptase. J. Med. Chem. 2015, 58, 4610-4623.
64. Di Santo, R.C.R.; Roux, A.; Artico, M.; Lavecchia, A.; Marinelli, L.; Novellino, E.; Palmisano, L.; Andreotti, M.; Amici, R.; Galluzzo, C.M.; et al. Novel bifunctional quinolonyl diketo acid derivatives as HIV-1 integrase inhibitors: Design, synthesis, biological activities, and mechanism of action. J. Med. Chem. 2006, 49, 1939-1945.
65. Di Santo, R. Diketo acids derivatives as dual inhibitors of human immunodeficiency virus type 1 integrase and the reverse transcriptase RNase H domain. Curr. Med. Chem. 2011, 18, 3335-3342.
66. Costi, R.M.M.; Chung, S.; Cuzzucoli Crucitti, G.; Maddali, K.; Pescatori, L.; Messore, A.; Madia, V.N.; Pupo, G.; Scipione, L.; Tortorella, S.; et al. Basic quinolinonyl diketo acid derivatives as inhibitors of hiv integrase and their activity against RNase H function of reverse transcriptase. J. Med. Chem. 2014, 57, 3223-3234.
67. Di Santo, R.C.R.; Roux, A.; Miele, G.; Cuzzucoli Crucitti, G.; Iacovo, A.; Rosi, F.; Lavecchia, A.; Marinelli, L.; Di Giovanni, C.; Novellino, E.; et al. Novel quinolinonyl diketo acid derivatives as HIV-1 integrase inhibitors: Design, synthesis, and biological activities. J. Med. Chem. 2008, 51, 4744-4750.
68. Fu, Y.; Yang, Y.; Zhou, S.; Liu, Y.; Yuan, Y.; Li, S.; Li, C. Ciprofloxacin containing Mannich base and its copper complex induce antitumor activity via different mechanism of action. Int. J. Oncol. 2014, 45, 2092-2100.
69. Boothe, D.; Boeckh, A.; Simpson, B.; Dubose, K. Comparison of pharmacodynamics and pharmacokinetic indices of efficacy for 5 fluoroquinolones toward pathogens of dogs and cats. J. Vet. Inter. Med. 2006, 20, 1297-1306.
70. Mueller, R.S.; Stephan, B. Pradofloxacin in the treatment of canine deep pyoderma: A multicentred, blinded, randomized parallel trial. Vet. Dermatol. 2007, 18, 144-151.
71. Champoux, J.J. DNA topoisomerases: Structure, function, and mechanism. Annu. Rev. Biochem. 2001, 70, 369-413.
72. Dale, A.G.; Hinds, J.; Mann, J.; Taylor, P.W.; Neidle, S. Symmetric bis-benzimidazoles are potent anti-staphylococcal agents with dual inhibitory mechanisms against DNA gyrase. Biochemistry 2012, 51, 5860-5871.
73. Deweese, J.E.; Osheroff, N. The DNA cleavage reaction of topoisomerase II: Wolf in sheep's clothing. Nucleic Acids Res. 2009, 37, 738-748.
74. Corbett, K.D.; Shultzaberger, R.K.; Berger, J.M. The c-terminal domain of DNA gyrase A adopts a DNA-bending beta-pinwheel fold. Proc. Natl. Acad. Sci. USA 2004, 101, 7293-7298.
75. Levine, C.; Hiasa, H.; Marians, K.J. DNA gyrase and topoisomerase IV: Biochemical activities, physiological roles during chromosome replication, and drug sensitivities. Biochim. Biophys. Acta 1998, 1400, 29-43.
76. Schoeffler, A.J.; Berger, J.M. DNA topoisomerases: Harnessing and constraining energy to govern chromosome topology. Q. Rev. Biophys. 2008, 41, 41-101.
77. Anderson, V.E.; Osheroff, N. Type II topoisomerases as targets for quinolone antibacterials turning Dr. Jekyll into Mr. Hyde. Curr. Pharm. Des. 2001, 7, 337-353.
78. Schoeffler, A.J.; Berger, J.M. Recent advances in understanding structure-function relationships in the type II topoisomerase mechanism. Biochem. Soc. Trans. 2005, 33, 1465-1470.
79. Schoeffler, A.J.; May, A.P.; Berger, J.M. A domain insertion in Escherichia coli gyrB adopts a novel fold that plays a critical role in gyrase function. Nucleic Acids Res. 2010, 38, 7830-7844.
80. Schmidt, B.H.; Burgin, A.B.; Deweese, J.E.; Osheroff, N.; Berger, J.M. A novel and unified two-metal mechanism for DNA cleavage by type II and Ia topoisomerases. Nature 2010, 465, 641-644.
81. Pitts, S.L.; Liou, G.F.; Mitchenall, L.A.; Burgin, A.B.; Maxwell, A.; Neuman, K.C.; Osheroff, N. Use of divalent metal ions in the DNA cleavage reaction of topoisomerase IV. Nucleic Acids Res. 2011, 39, 4808-4817.
82. Deweese, J.E.; Osheroff, M.A.; Osheroff, N. DNA topology and topoisomerases. Biochem. Mol. Biol. Educ. 2009, 37, 2-10.
83. Laponogov, I.; Pan, X.-S.; Veselkov, D.A.; McAuley, K.E.; Fisher, L.M.; Sanderson, M.R. Structural basis of gate-DNA breakage and resealing by type II topoisomerases. PLoS ONE 2010, 5, e11338.
84. Laponogov, I.; Sohi, M.K.; Veselkov, D.; Pan, X.; Sawhney, R.; Thompson, A.; McAuley, K.; Fisher, L.; Sanderson, M. Structural insight into the quinolone-DNA cleavage complex of type IIa topoisomerases. Nat. Struct. Mol. Biol. 2009, 16, 667-669.
85. Baker, N.M.; Weigand, S.; Maar-Mathias, S.; Mondragon, A. Solution structures of DNA-bound gyrase. Nucleic Acids Res. 2011, 39, 755-766.
86. Aldred, K.J.; Schwanz, H.A.; Li, G.; Williamson, B.H.; McPherson, S.A.; Turnbough, C.L., Jr.; Kerns, R.J.; Osheroff, N. Activity of quinolone cp-115,955 against bacterial and human type II topoisomerases is mediated by different interactions. Biochemistry 2015, 54, 1278-1286.
87. Kreuzer, K.N.; Cozzarelli, N.R. Escherichia coli mutants thermosensitive for deoxyribonucleic acid gyrase subunit A: Effects on deoxyribonucleic acid replication, transcription, and bacteriophage growth. J. Bacteriol. 1979, 140, 424-435.
88. Hooper, D.C. Mechanisms of Quinolone Resistance. In Quinolone Antimicrobial Agents, 3rd ed.; ASM Press: Washington, DC, USA, 2003; pp. 41-67.
89. Hooper, D.C.; Jacoby, G.A. Mechanisms of drug resistance: Quinolone resistance. Ann. N. Y. Acad. Sci. 2015, 1354, 12-31.
90. Fournier, B.; Zhao, X.; Lu, T.; Drlica, K.; Hooper, D.C. Selective targeting of topoisomerase iv and DNA gyrase in Staphylococcus aureus: Different patterns of quinolone-induced inhibition of DNA synthesis. Antimicrob. Agents Chemother. 2000, 44, 2160-2165.
91. Price, L.B.; Vogler, A.; Pearson, T.; Busch, J.D.; Schupp, J.M.; Keim, P. In vitro selection and characterization of Bacillus anthracis mutants with high-level resistance to ciprofloxacin. Antimicrob. Agents Chemother. 2003, 47, 2362-2365.
92. Morgan-Linnell, S.K.; Boyd, L.B.; Steffen, D.; Zechiedrich, L. Mechanisms accounting for fluoroquinolone resistance in Escherichia coli clinical isolates. Antimicrob. Agents Chemother. 2009, 53, 235-241.
93. Sissi, C.; Perdona, E.; Domenici, E.; Feriani, A.; Howells, A.J.; Maxwell, A.; Palumbo, M. Ciprofloxacin affects conformational equilibria of DNA gyrase A in the presence of magnesium ions. J. Mol. Biol. 2001, 311, 195-203.
94. Sissi, C.; Palumbo, M. Effects of magnesium and related divalent metal ions in topoisomerase structure and function. Nucleic Acids Res. 2009, 37, 702-711.
95. Barnard, F.M.; Maxwell, A. Interaction between DNA gyrase and quinolones: Effects of alanine mutations at gyrA subunit residues Ser83 and Asp87. Antimicrob. Agents Chemother. 2001, 45, 1994-2000.
96. Chan, P.F.; Srikannathasan, V.; Huang, J.; Cui, H.; Fosberry, A.P.; Gu, M.; Hann, M.M.; Hibbs, M.; Homes, P.; Ingraham, K.; et al. Structural basis of DNA gyrase inhibition by antibacterial QPT-1, anticancer drug etoposide and moxifloxacin. Nat. Commun. 2015, 6.
97. Bax, B.C.P.; Eggleston, D.; Fosberry, A.; Gentry, D.; Gorrec, F.; Giordano, I.; Hann, M.; Hennessy, A.; Hibbs, M.; Huang, J.; et al. Type IIa topoisomerase inhibition by a new class of antibacterial agents. Nature 2010, 466, 935-940.
98. Srikannathasan, V.; Wohlkonig, A.; Shillings, A.; Singh, O.; Chan, P.F.; Huang, J.; Gwynn, M.N.; Fosberry, A.P.; Homes, P.; Hibbs, M.; et al. Crystallization and initial crystallographic analysis of covalent DNA-cleavage complexes of Staphyloccocus aureus DNA gyrase with QPT-1, moxifloxacin and etoposide. Acta Crystallogr. F Struct. Biol. Commun. 2015, 71, 1242-1246.
99. Wohlkonig, A. Structural basis of quinolone inhibition of type IIa topoisomerases and target-mediated resistance. Nat. Struct. Mol. Biol. 2010, 17, 1152-1153.
100. Collin, F.; Karkare, S.; Maxwell, A. Exploiting bacterial DNA gyrase as a drug target: Current state and perspectives. Appl. Microbiol. Biotechnol. 2011, 92, 479-497.
101. Aldred, K.J.; Breland, E.J.; Vlckova, V.; Strub, M.-P.; Neuman, K.C.; Kerns, R.J.; Osheroff, N. Role of the water metal ion bridge in mediating interactions between quinolones and Escherichia coli topoisomerase IV. Biochemistry 2014, 53, 5558-5567.
102. Aldred, K.J.; McPherson, S.A.; Turnbough, C.L., Jr.; Kerns, R.J.; Osheroff, N. Topoisomerase IV-quinolone interactions are mediated through a water-metal ion bridge: Mechanistic basis of quinolone resistance. Nucleic Acids Res. 2013, 41, 4628-4639.
103. Aldred, K.J.; McPherson, S.A.; Wang, P.; Kerns, R.J.; Graves, D.E.; Turnbough, C.L., Jr.; Osheroff, N. Drug interactions with Bacillus anthracis topoisomerase IV: Biochemical basis for quinolone action and resistance. Biochemistry 2012, 51, 370-381.
104. Aldred, K.J.; Schwanz, H.A.; Li, G.; McPherson, S.A.; Turnbough, C.L., Jr.; Kerns, R.J.; Osheroff, N. Overcoming target-mediated quinolone resistance in topoisomerase IV by introducing metal-ion-independent drug-enzyme interactions. ACS Chem. Biol. 2013, 8, 2660-2668.
105. Baldwin, E.L.; Osheroff, N. Etoposide, topoisomerase ii and cancer. Curr. Med. Chem. Anticancer Agents 2005, 5, 363-372.
106. Hsiung, Y.; Elsea, S.H.; Osheroff, N.; Nitiss, J.L. A mutation in yeast top2 homologous to a quinolone-resistant mutation in bacteria. Mutation of the amino acid homologous to Ser83 of Escherichia coli GyrA alters sensitivity to eukaryotic topoisomerase inhibitors. J. Biol. Chem. 1995, 270, 20359-20364.
107. Lee, S.; Jung, S.-R.; Heo, K.; Byl, J.A.W.; Deweese, J.E.; Osheroff, N.; Hohng, S. DNA cleavage and opening reactions of human topoisomerase iiα are regulated via Mg2+ -mediated dynamic bending of gate-DNA. Proc. Natl. Acad. Sci. USA 2012, 109, 2925-2930.
108. Schmidt, B.H.; Osheroff, N.; Berger, J.M. Structure of a topoisomerase ii-DNA-nucleotide complex reveals a new control mechanism for ATPase activity. Nat. Struct. Mol. Biol. 2012, 19, 1147-1154.
109. Jacoby, G.A. Mechanisms of resistance to quinolones. Clin. Infect. Dis. 2005, 41, 120-126.
110. Redgrave, L.S.; Sutton, S.B.; Webber, M.A.; Piddock, L.J. Fluoroquinolone resistance: Mechanisms, impact on bacteria, and role in evolutionary success. Trends Micobiol. 2014, 22, 438-445.
111. Pan, X.-S.; Gould, K.A.; Fisher, L.M. Probing the differential interactions of quinazolinedione pd 0305970 and quinolones with gyrase and topoisomerase IV. Antimicrob. Agents Chemother. 2009, 53, 3822-3831.
112. Yague, G.; Morris, J.E.; Pan, X.-S.; Gould, K.A.; Fisher, L.M. Cleavable-complex formation by wild-type and quinolone-resistant streptococcus pneumoniae type II topoisomerases mediated by gemifloxacin and other fluoroquinolones. Antimicrob. Agents Chemother. 2002, 46, 413-419.
113. Pfeiffer, E.S.; Hiasa, H. Determination of the primary target of a quinolone drug and the effect of quinolone resistance-conferring mutations by measuring quinolone sensitivity based on its mode of action. Antimicrob. Agents Chemother. 2007, 51, 3410-3412.
114. Drlica, K.; Hiasa, H.; Kerns, R.; Malik, M.; Mustaev, A.; Zhao, X. Quinolones: Action and resistance updated. Curr. Top. Med. Chem. 2009, 9, 981-988.
115. Wang, M.; Tran, J.H.; Jacoby, G.A.; Zhang, Y.; Wang, F.; Hooper, D.C. Plasmid-mediated quinolone resistance in clinical isolates of Escherichia coli from shanghai, china. Antimicrob. Agents Chemother. 2003, 47, 2242-2248.
116. Rodriguez-Martinez, J.M.; Cano, M.E.; Velasco, C.; Martinez-Martinez, L.; Pascual, A. Plasmid-mediated quinolone resistance: An update. J. Infect. Chemother. 2011, 17, 149-182.
117. Li, Z.; Deguchi, T.; Yasuda, M.; Kawamura, T.; Kanematsu, E.; Nishino, Y.; Ishihara, S.; Kawada, Y. Alteration in the gyra subunit of DNA gyrase and the parc subunit of DNA topoisomerase IV in quinolone-resistant clinical isolates of Staphylococcus epidermidis. Antimicrob. Agents Chemother. 1998, 42, 3293-3295.
118. Robicsek, A.; Jacoby, G.A.; Hooper, D.C. The worldwide emergence of plasmid-mediated quinolone resistance. Lancet Infect. Dis. 2006, 6, 629-640.
119. Strahilevitz, J.; Jacoby, G.A.; Hooper, D.C.; Robicsek, A. Plasmid-mediated quinolone resistance: A multifaceted threat. Clin. Microbiol. Rev. 2009, 22, 664-689.
120. Martinez-Martinez, L.; Pascual, A.; Jacoby, G.A. Quinolone resistance from a transferable plasmid. Lancet 1998, 351, 797-799.
121. Tran, J.H.; Jacoby, G.A. Mechanism of plasmid-mediated quinolone resistance. Proc. Natl. Acad. Sci. USA 2002, 99, 5638-5642.
122. Xiong, X.; Bromley, E.H.C.; Oelschlaeger, P.; Woolfson, D.N.; Spencer, J. Structural insights into quinolone antibiotic resistance mediated by pentapeptide repeat proteins: Conserved surface loops direct the activity of a qnr protein from a gram-negative bacterium. Nucleic Acids Res. 2011, 39, 3917-3927.
123. Guillard, T.; Cambau, E.; Chau, F.; Massias, L.; de Champs, C.; Fantin, B. Ciprofloxacin treatment failure in a murine model of pyelonephritis due to an AAC (6')-Ib-cr-producing Escherichia coli strain susceptible to ciprofloxacin in vitro. Antimicrob. Agents Chemother. 2013, 57, 5830-5835.
124. Poole, K. Efflux pumps as antimicrobial resistance mechanisms. Ann. Med. 2007, 39, 162-176.
125. Goldman, J.D.; White, D.G.; Levy, S.B. Multiple antibiotic resistance (mar) locus protects Escherichia coli from rapid cell killing by fluoroquinolones. Antimicrob. Agents Chemother. 1996, 40, 1266-1269.